Patents by Inventor Juergen Reindl

Juergen Reindl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-ALPHA-V INTEGRIN ANTIBODY FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20190263913
    Abstract: The invention is directed to the treatment of prostate cancer by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from prostate cancer, especially castration-resistant prostate cancer (CRPC), optionally accompanied by lymph node and bone tissue metastases (mCRPC). In particular, the invention relates to the therapy of said patients by means of the anti-angiogenic antibody DI17E6 and structural mutants thereof.
    Type: Application
    Filed: January 25, 2019
    Publication date: August 29, 2019
    Inventors: Axel Hoffmann, Heinrich Lannert, Klaus Brischwein, Frederic Christian Pipp, Juergen Reindl, Karin Groll, Michael Zuehlsdorf, Otmar Pfaff, Sabine Raab, Ulrike Dau, Benoit Destenaves
  • ANTI-ALPHA-V INTEGRIN ANTIBODY FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20170218070
    Abstract: The invention is directed to the treatment of prostate cancer by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from prostate cancer, especially castration-resistant prostate cancer (CRPC), optionally accompanied by lymph node and bone tissue metastases (mCRPC). In particular, the invention relates to the therapy of said patients by means of the anti-angiogenic antibody DI17E6 and structural mutants thereof.
    Type: Application
    Filed: January 9, 2017
    Publication date: August 3, 2017
    Applicant: Merck Patent GmbH
    Inventors: Axel Hoffmann, Heinrich Lannert, Klaus Brischwein, Frederic Christian Pipp, Juergen Reindl, Karin Groll, Michael Zuehlsdorf, Otmar Pfaff, Sabine Raab, Ulrike Dau, Benoit Destenaves
  • Anti-alpha-V integrin antibody for the treatment of prostate cancer
    Patent number: 9555110
    Abstract: The invention is directed to the treatment of prostate cancer by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from prostate cancer, especially castration-resistant prostate cancer (CRPC), optionally accompanied by lymph node and bone tissue metastases (mCRPC). In particular, the invention relates to the therapy of said patients by means of the anti-angiogenic antibody DI17E6 and structural mutants thereof.
    Type: Grant
    Filed: February 7, 2012
    Date of Patent: January 31, 2017
    Assignee: Merck Patent GmbH
    Inventors: Axel Hoffmann, Heinrich Lannert, Klaus Brischwein, Frederic Christian Pipp, Juergen Reindl, Karin Groll, Michael Zuehlsdorf, Otmar Pfaff, Sabine Raab, Ulrike Dau, Benoit Destenaves
  • ANTI-ALPHA-V INTEGRIN ANTIBODY FOR THE TREATMENT OF PROSTATE CANCER
    Publication number: 20140086908
    Abstract: The invention is directed to the treatment of prostate cancer by means of antibodies. Above all, the invention relates to the administration of an anti-alpha-v integrin (receptor) antibody to patients suffering from prostate cancer, especially castration-resistant prostate cancer (CRPC), optionally accompanied by lymph node and bone tissue metastases (mCRPC). In particular, the invention relates to the therapy of said patients by means of the anti-angiogenic antibody DI17E6 and structural mutants thereof.
    Type: Application
    Filed: February 7, 2012
    Publication date: March 27, 2014
    Applicant: Merck Patent GmbH
    Inventors: Axel Hoffmann, Heinrich Lannert, Klaus Brischwein, Frederic Christian Pipp, Juergen Reindl, Karib Groll, Michael Zuehlsdorf, Otmar Pfaff, Sabine Raab, Ulrike Dau, Benoit Destenaves